ReviewInflammatory bowel diseases2015
Biomarkers of Inflammatory Bowel Disease: From Classical Laboratory Tools to Personalized Medicine.
Review in Inflammatory bowel diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Intestinal Biomarkers and Their Importance in Canine Enteropathies.Veterinary medicine international · 2024Review
- Modeling of Treatment Outcomes with Tofacitinib Maintenance Therapy in Patients with Ulcerative Colitis: A Post Hoc Analysis of Data from the OCTAVE Clinical Program.Advances in therapy · 2023Article
- The Current Status of Molecular Biomarkers for Inflammatory Bowel Disease.Biomedicines · 2022Review
- Proteomic Analysis of Potential Targets for Non-Response to Infliximab in Patients With Ulcerative Colitis.Frontiers in pharmacology · 2022Article
- Crohn's disease-related single nucleotide polymorphisms are associated with ileal pouch afferent limb stenosis.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2021Article
- Proteomic insights on the metabolism in inflammatory bowel disease.World journal of gastroenterology · 2020Review
- Precision medicine in inflammatory bowel disease: concept, progress and challenges.F1000Research · 2020Review
- Common functional alterations identified in blood transcriptome of autoimmune cholestatic liver and inflammatory bowel diseases.Scientific reports · 2019Article
- Article
- Biomarker discovery in inflammatory bowel diseases using network-based feature selection.PloS one · 2019Article
- Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.International journal of molecular sciences · 2018Review
- Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs.Journal of veterinary internal medicine · 2018Review
- Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases.Gastroenterology and hepatology from bed to bench · 2018Article
- Serum miRNA signature diagnoses and discriminates murine colitis subtypes and predicts ulcerative colitis in humans.Scientific reports · 2017Article
- Do ginger-derived nanoparticles represent an attractive treatment strategy for inflammatory bowel diseases?Nanomedicine (London, England) · 2016Article
- Serum Calprotectin: A Novel Diagnostic and Prognostic Marker in Inflammatory Bowel Diseases.The American journal of gastroenterology · 2016Article
- Serum proteome profiles in cats with chronic enteropathies.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Diagnostics of inflammatory bowel diseases (IBDs) currently relies on a combination of biological and morphological tests. The current method of diagnostic remains a critical challenge for physicians in part due to their invasiveness and also for their limitations in term of diagnosis, prognosis, disease activity and severity assessment, and therapeutic outcomes. Laboratory biomarkers can be used in the diagnosis and management of IBD, but none of them has been proven to be ideal. Increasing efforts are being made to discover new biomarkers that can discriminate between the types of IBD, predict future responses to treatment, and aid in differential diagnosis, treatment planning, and prognosis prediction. This review addresses the potential for current biomarkers and the emergence of the concept of biomarker signatures in IBD diagnostic and personalized medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.